<DOC>
	<DOCNO>NCT02228733</DOCNO>
	<brief_summary>This single ascending dose ( SAD ) study healthy subject evaluate safety , tolerability pharmacokinetics KBP-5074 . PK/PD ( plasma aldosterone , serum potassium urine albumin level ) relationship explore support selection dose regimen KBP-5074 suitable Phase 2 dose-finding study evaluate efficacy , safety tolerability KBP-5074 patient could slow progression nephropathy well control hypertension .</brief_summary>
	<brief_title>Phase 1 Single Ascending Dose Study Evaluate Safety , Tolerability Pharmacokinetics KBP-5074</brief_title>
	<detailed_description>This open-label , parallel-group , dose-escalation study evaluate safety , tolerability pharmacokinetics KBP-5074 follow single dose administration KBP-5074 without food . The study include 2 part . Part 1 : Pharmacokinetics dose cohort characterize initiation dose subsequent cohort . Eight subject dose cohort receive active drug . The total number cohort 5 . Extensive PK sampling collect prior follow administration single dose KBP-5074 . Part 2 : A separate panel 6 subject receive single dose KBP-5074 fed condition . Extensive PK sampling collect prior follow administration single dose KBP-5074 fed condition . Serum plasma sample pharmacodynamic marker ( plasma aldosterone serum potassium level ) collect pre-dose postdose Part 1 Part 2 . The urine sample also use quantitative determination urinary albumin Part 1 Part 2 . Safety assessment include monitor adverse event ( AEs ) , vital sign ( blood pressure , pulse rate , respiratory rate oral temperature ) , clinical laboratory finding , 12-lead electrocardiogram ( ECGs ) , physical examination finding .</detailed_description>
	<criteria>Body mass index ( BMI ) 19 ≤ BMI ≤ 30 kg/m2 , significant medical history , normal renal function good general health Clinically significant history gastrointestinal , cardiovascular , musculoskeletal , endocrine , hematologic , psychiatric , renal , hepatic , bronchopulmonary , neurologic , immunologic , lipid metabolism disorder , drug hypersensitivity ; A history prescription drug abuse , illicit drug use within 6 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>